Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujing Yuan

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Nature|November 15, 2023
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancerPeipei Zhou, Hao Shi, Hongling Huang, et al.
Nature|July 5, 2023
SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunityChuansheng Guo, Zhiyuan You, Hao Shi, et al.
Nature|March 20, 2025
VDAC2 loss elicits tumour destruction and inflammation for cancer therapySujing Yuan, Renqiang Sun, Hao Shi, et al.
EMBO Molecular Medicine|December 13, 2021
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancerQian Zhou, Jinxia Liang, Tong Yang, et al.
Cancer Immunology Research|February 20, 2021
DGKA Mediates Resistance to PD-1 BlockadeLingyi Fu, Sen Li, WeiWei Xiao, et al.
Ebiomedicine|November 6, 2022
Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2Xiao Hu, Yanli Zou, David A Copland, et al.
Nature|June 22, 2022
cBAF complex components and MYC cooperate early in CD8<sup>+</sup> T cell fateAo Guo, Hongling Huang, Zhexin Zhu, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Nature|November 15, 2023
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancerPeipei Zhou, Hao Shi, Hongling Huang, et al.
Nature|July 5, 2023
SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunityChuansheng Guo, Zhiyuan You, Hao Shi, et al.
Nature|March 20, 2025
VDAC2 loss elicits tumour destruction and inflammation for cancer therapySujing Yuan, Renqiang Sun, Hao Shi, et al.
EMBO Molecular Medicine|December 13, 2021
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancerQian Zhou, Jinxia Liang, Tong Yang, et al.
Cancer Immunology Research|February 20, 2021
DGKA Mediates Resistance to PD-1 BlockadeLingyi Fu, Sen Li, WeiWei Xiao, et al.
Ebiomedicine|November 6, 2022
Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2Xiao Hu, Yanli Zou, David A Copland, et al.
Nature|June 22, 2022
cBAF complex components and MYC cooperate early in CD8<sup>+</sup> T cell fateAo Guo, Hongling Huang, Zhexin Zhu, et al.
Pageof 2